LARVOL Appoints New Vice President, Global Sales
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SAN FRANCISCO--(BUSINESS WIRE)-- LARVOL, leading provider of intelligence and data solutions to pharma and life science teams, today welcomes Mark Lagunowich as Vice President, Global Sales.
“We are thrilled to welcome Mark to the team at LARVOL,” said founder and CEO Bruno Larvol. “I have been so impressed by Mark’s skills as a sales executive, and this is the perfect time for us to bring on someone of his caliber.”
Lagunowich brings over 30 years of experience in the life science industry to his role at LARVOL. Most recently, he led the Americas Life Science Sales Team for Clarivate Analytics. Prior to that, he spent 8 years as Global VP of Sales at Sparta Systems, and has sold a wide variety of business solutions to pharmaceutical, medical device, and clinical research (CRO) companies.
“I am excited to join Bruno and an incredibly impressive team at LARVOL,” said Lagunowich. “At a time when researchers and pharma companies need to make critical decisions faster than ever, LARVOL solutions are uniquely positioned to provide our customers with critical data using combination of cutting-edge AI and expert curation. LARVOL is strong, fast, and on a mission. I am thrilled to be here.”
Lagunowich rounds out several important new hires for LARVOL including HR and Marketing leadership roles as the company prepares to launch additional oncology-focused solutions this year. VIEW, the first social listening platform aimed at capturing the conversations of oncology opinion leaders on Twitter, will launch at ScaleUp 360 in April. CLIN, a complete database of immuno-oncology clinical trial data will also launch this spring.
About LARVOL:
LARVOL provides SaaS solutions to support the data and intelligence needs of the pharmaceutical and biotech industry. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The 100% remote LARVOL team includes MDs, PhDs, and industry professionals who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis. For more information, visit LARVOL.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005215/en/
Abby Fraser Abigail.fraser@larvol.com + 615 973 6241
Source: LARVOL
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GeoPark Limited Announces the Successful Early Tender Results of Its Cash Tender Offer for up to US$255,000,000 of Its 6.500% Senior Notes Due 2024 and Solicitation of Consents for Proposed Amendments
- Child Care Advocates Call on Premier Doug Ford to Cooperate With the Federal Government
- CORRECTING and REPLACING Notice of Lead Plaintiff Deadline for Shareholders in the Romeo Power Inc. Class Action Lawsuit
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!